Physician profile
Pedro F Badillo
NPI 1902808678
$2,308.50
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $582 · 2021: $566 · 2022: $242 · 2023: $114 · 2024: $57.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $541.75 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $506.70 | 2019-2022 | |
| Amgen INC. | $430.91 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $214.19 | 2019-2023 | |
| Abbott Laboratories | $123.71 | 2020-2024 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $117.78 | 2019-2021 | |
| Amarin Pharma, INC. | $81.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $53.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $47.91 | 2019-2021 | |
| Medtronic, INC. | $41.85 | 2022 | |
| Pfizer INC. | $36.55 | 2019 | |
| Tactile Systems Technology INC | $24.00 | 2020 | |
| Merck Sharp & Dohme LLC | $20.00 | 2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $18.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.00 | 2019 | |
| Boston Scientific Corporation | $14.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Badillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.